Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation

Rosaria Calia; C Lai; P Aceto; M Luciani; Jacopo Romagnoli; S Lai; A Gargiulo; Franco Citterio

doi:10.1016/j.transproceed.2011.03.048

Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation

Rosaria Calia
, C Lai
, P Aceto
, M Luciani
, Jacopo Romagnoli
, S Lai
, A Gargiulo
, Franco Citterio

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

This study investigated whether switching from the twice-daily (Prograf; TAC) to the once-daily formulation of tacrolimus with extended release (Advagraf; XL) affected quality of life, anxiety, and transplant benefit perception after allogeneic kidney transplantation.

Lingua originale	Inglese
pagine (da-a)	1020-1023
Numero di pagine	4
Rivista	Transplantation Proceedings
Volume	43
DOI	https://doi.org/10.1016/j.transproceed.2011.03.048
Stato di pubblicazione	Pubblicato - 2011

Keywords

Adult
Aged
Analysis of Variance
Anxiety
Delayed-Action Preparations
Drug Administration Schedule
Drug Monitoring
Female
Graft Rejection
Health Knowledge, Attitudes, Practice
Humans
Immunosuppressive Agents
Italy
Kidney Transplantation
Male
Middle Aged
Perception
Psychiatric Status Rating Scales
Quality of Life
Questionnaires
Tacrolimus
Time Factors
Treatment Outcome
Truth Disclosure

Accesso al documento

10.1016/j.transproceed.2011.03.048

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{681c96e3954d438286376438cee9c352,

title = "Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation",

abstract = "This study investigated whether switching from the twice-daily (Prograf; TAC) to the once-daily formulation of tacrolimus with extended release (Advagraf; XL) affected quality of life, anxiety, and transplant benefit perception after allogeneic kidney transplantation.",

keywords = "Adult, Aged, Analysis of Variance, Anxiety, Delayed-Action Preparations, Drug Administration Schedule, Drug Monitoring, Female, Graft Rejection, Health Knowledge, Attitudes, Practice, Humans, Immunosuppressive Agents, Italy, Kidney Transplantation, Male, Middle Aged, Perception, Psychiatric Status Rating Scales, Quality of Life, Questionnaires, Tacrolimus, Time Factors, Treatment Outcome, Truth Disclosure, Adult, Aged, Analysis of Variance, Anxiety, Delayed-Action Preparations, Drug Administration Schedule, Drug Monitoring, Female, Graft Rejection, Health Knowledge, Attitudes, Practice, Humans, Immunosuppressive Agents, Italy, Kidney Transplantation, Male, Middle Aged, Perception, Psychiatric Status Rating Scales, Quality of Life, Questionnaires, Tacrolimus, Time Factors, Treatment Outcome, Truth Disclosure",

author = "Rosaria Calia and C Lai and P Aceto and M Luciani and Jacopo Romagnoli and S Lai and A Gargiulo and Franco Citterio",

year = "2011",

doi = "10.1016/j.transproceed.2011.03.048",

language = "English",

volume = "43",

pages = "1020--1023",

journal = "Transplantation Proceedings",

issn = "0041-1345",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation

AU - Calia, Rosaria

AU - Lai, C

AU - Aceto, P

AU - Luciani, M

AU - Romagnoli, Jacopo

AU - Lai, S

AU - Gargiulo, A

AU - Citterio, Franco

PY - 2011

Y1 - 2011

N2 - This study investigated whether switching from the twice-daily (Prograf; TAC) to the once-daily formulation of tacrolimus with extended release (Advagraf; XL) affected quality of life, anxiety, and transplant benefit perception after allogeneic kidney transplantation.

AB - This study investigated whether switching from the twice-daily (Prograf; TAC) to the once-daily formulation of tacrolimus with extended release (Advagraf; XL) affected quality of life, anxiety, and transplant benefit perception after allogeneic kidney transplantation.

KW - Adult

KW - Aged

KW - Analysis of Variance

KW - Anxiety

KW - Delayed-Action Preparations

KW - Drug Administration Schedule

KW - Drug Monitoring

KW - Female

KW - Graft Rejection

KW - Health Knowledge, Attitudes, Practice

KW - Humans

KW - Immunosuppressive Agents

KW - Italy

KW - Kidney Transplantation

KW - Male

KW - Middle Aged

KW - Perception

KW - Psychiatric Status Rating Scales

KW - Quality of Life

KW - Questionnaires

KW - Tacrolimus

KW - Time Factors

KW - Treatment Outcome

KW - Truth Disclosure

KW - Adult

KW - Aged

KW - Analysis of Variance

KW - Anxiety

KW - Delayed-Action Preparations

KW - Drug Administration Schedule

KW - Drug Monitoring

KW - Female

KW - Graft Rejection

KW - Health Knowledge, Attitudes, Practice

KW - Humans

KW - Immunosuppressive Agents

KW - Italy

KW - Kidney Transplantation

KW - Male

KW - Middle Aged

KW - Perception

KW - Psychiatric Status Rating Scales

KW - Quality of Life

KW - Questionnaires

KW - Tacrolimus

KW - Time Factors

KW - Treatment Outcome

KW - Truth Disclosure

UR - http://hdl.handle.net/10807/52030

U2 - 10.1016/j.transproceed.2011.03.048

DO - 10.1016/j.transproceed.2011.03.048

M3 - Article

SN - 0041-1345

VL - 43

SP - 1020

EP - 1023

JO - Transplantation Proceedings

JF - Transplantation Proceedings

ER -

Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo